{"id":"W4416507969","doi":"10.1182/bloodadvances.2025017083","title":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"Genentech; Servier; Astellas Pharma; Nippon Shinyaku; Incyte; BeiGene; Astex Pharmaceuticals; Celgene; Amgen; Ariad Pharmaceuticals; Ascentage Pharma; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Venetoclax; Cytarabine; Myeloid leukemia; Azacitidine; NPM1; Population; Chemotherapy; Chemotherapy regimen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001029184,0.0000949568,0.0002392894,0.0001495557,0.00002567865,0.000006111718,0.00005766737,0.00004220885,0.000003978935],"category_scores_gemma":[0.0002164275,0.00007130392,0.00001956586,0.0002799811,0.00009845495,0.00009524947,0.00001483656,0.0001107034,4.57007e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006469551,"about_ca_system_score_gemma":0.000205562,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004506016,"about_ca_topic_score_gemma":0.00004307936,"domain_scores_codex":[0.9992973,0.0000178682,0.0002016887,0.0002118508,0.0001266072,0.0001447131],"domain_scores_gemma":[0.9991898,0.000105932,0.00009555815,0.0001759619,0.0003970196,0.00003574252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004569493,0.0003675971,0.940469,0.0006533217,0.0001577594,0.000002445367,0.0003603695,0.000119879,0.006957528,0.0002848977,0.0002179026,0.04583986],"study_design_scores_gemma":[0.02299292,0.001625911,0.8864174,0.000569294,0.0001094975,0.000001354956,0.0004443989,0.0006714777,0.08443622,0.00120834,0.001382408,0.0001407297],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970598,0.0009468655,0.0003354903,0.0003388891,0.00002042835,0.001078836,0.00002569054,0.00001181051,0.0001822155],"genre_scores_gemma":[0.9949903,0.0007267018,0.003772391,0.0001761412,0.00001902558,0.00008231794,0.00004853209,0.00001127576,0.0001732688],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07747869,"threshold_uncertainty_score":0.290769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005691558317478645,"score_gpt":0.2824183766750267,"score_spread":0.2767268183575481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}